Structure Therapeutics Inc.
NASDAQ:GPCRBiotechnology
+$0.39 today
- Market cap
- $999.36M
- Beta
- -1.42
- P/E (TTM)
- -19.3
- EPS (TTM)
- -$2.35
Volume 1.10M
Average 0.87M
GPCR Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Structure Therapeutics Inc.NASDAQ: GPCR
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow growth accelerates
Q2 FY2026 free cash flow of $106.02M (cash outflow) rose 93.5% year over year, ahead of the +28.1% change in trailing-twelve-month free cash flow. Over 3 fiscal years it compounded at +69.6% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +93.5% holds above the trailing-twelve-month pace of +28.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (225.81M) USD
- Year-over-year change
- -91.5%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (225.81M) | -91.5% |
| FY2024 | 2024-12-31 | (117.93M) | -44.4% |
| FY2023 | 2023-12-31 | (81.66M) | -76.5% |
| FY2022 | 2022-12-31 | (46.28M) | -38.7% |
| FY2021 | 2021-12-31 | (33.37M) | — |
Free Cash Flow vs competitors
How GPCR compares with its peers on the latest reported figures
- GPCR's LTM Jun 2026 free cash flow of $210.41M is the largest of the 8 companies compared; the peer median is $88.63M.
- Its year-over-year change of +28.1% is the 2nd highest of 7, against a peer median of -53.3%.
- Over three fiscal years its annual growth of +69.6% compares with a peer median of +18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $210.41M | +28.1% | +69.6% | — | |
| LTM Jun 2026 | $138.8M | -28.0% | +69.6% | — | |
KLRAKailera Therapeutics, Inc. | FY2025 | $122.3M | — | — | — |
| LTM Mar 2026 | $122.13M | -277.7% | +3.7% | 610.6% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $88.63M | +64.1% | +31.4% | 859.1% |
SEPNSepterna, Inc. | LTM Sep 2026 | $77.59M | -175.2% | — | 80.6% |
| LTM Mar 2026 | $56.25M | -50.6% | +3.5% | — | |
| LTM Mar 2026 | $10.41M | -56.0% | +18.3% | 28.3% | |
| Peer median (excluding GPCR) | $88.63M | -53.3% | +18.3% | 345.6% | |
Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (38.05M) | (51.32M) | (89.62M) | (122.53M) | (141.2M) |
| Depreciation & Amortization | 72K | 277K | 295K | 992K | 1.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.49M | 2.51M | 8.19M | 18.79M | 28.99M |
| Change in Working Capital | 4.06M | 2.97M | 6.97M | 2.96M | (88.27M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.9M | 2.15M | (859.25K) | 3.31M | 4.77M |
| Other Working Capital | 2.17M | 815K | 7.83M | (343K) | (93.05M) |
| Other Non-Cash Items | 268K | (558K) | (5.32M) | (16.86M) | (23.05M) |
| Operating Cash Flow | (32.16M) | (46.12M) | (79.49M) | (116.64M) | (222.2M) |
| Capital Expenditures | (1.21M) | (155K) | (2.17M) | (1.29M) | (3.61M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (4.21M) | (123.45M) | (416.99M) | (702.52M) | (547.38M) |
| Sales of Investments | 23.28M | 61.5M | 151.05M | 344.9M | 630.54M |
| Other Investing Activities | 0 | 0 | (231.38K) | 0 | 10.25M |
| Investing Cash Flow | 17.86M | (62.11M) | (268.34M) | (358.91M) | 89.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 472.3M | 514.57M | 767.18M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (104K) | (2.49M) | (20.77M) | 690K | (4.66M) |
| Financing Cash Flow | 103.25M | 29.01M | 451.53M | 515.26M | 762.52M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (1.66M) |
| Net Change in Cash | 88.95M | (79.21M) | 103.7M | 39.72M | 630.12M |
| Free Cash Flow | (33.37M) | (46.28M) | (81.66M) | (117.93M) | (225.81M) |
Structure Therapeutics Inc.
NASDAQ:GPCR
Intrinsic Alpha fair value
Locked
Current Price
$17.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.